Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the years ended December 31, 2016, 2015 and 2014.

	Year Ended December 31, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	11,529	$	22,307	$	33,836
Oragenics, Inc.	1,047		1,705		2,752
Fibrocell Science, Inc.	2,419		3,523		5,942
Genopaver, LLC	273		5,844		6,117
S & I Ophthalmic, LLC	—		6,141		6,141
OvaXon, LLC	—		2,934		2,934
Intrexon Energy Partners, LLC	2,500		15,052		17,552
Persea Bio, LLC	500		778		1,278
Ares Trading S.A.	6,389		3,803		10,192
Thrive Agrobiotics, Inc.	185		1,529		1,714
Intrexon Energy Partners II, LLC	2,000		1,169		3,169
Exotech Bio, Inc.	417		375		792
Relieve Genetics, Inc.	361		878		1,239
Intrexon T1D Partners, LLC	821		1,087		1,908
AD Skincare, Inc.	241		454		695
Genten Therapeutics, Inc.	122		264		386
CRS Bio, Inc.	57		91		148
Other	5,572		7,504		13,076
Total	$	34,433	$	75,438	$	109,871

	Year Ended December 31, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	2,855	$	16,451	$	19,306
Oragenics, Inc.	5,679		856		6,535
Fibrocell Science, Inc.	6,046		6,133		12,179
Genopaver, LLC	273		3,556		3,829
S & I Ophthalmic, LLC	—		4,115		4,115
OvaXon, LLC	—		2,540		2,540
Intrexon Energy Partners, LLC	2,500		10,947		13,447
Persea Bio, LLC	500		741		1,241
Ares Trading S.A.	3,933		795		4,728
Thrive Agrobiotics, Inc.	46		220		266
Intrexon Energy Partners II, LLC	167		—		167
Other	10,514		8,954		19,468
Total	$	32,513	$	55,308	$	87,821

	Year Ended December 31, 2014
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	2,577	$	12,044	$	14,621
Oragenics, Inc.	1,045		598		1,643
Fibrocell Science, Inc.	1,794		4,398		6,192
Genopaver, LLC	273		1,510		1,783
S & I Ophthalmic, LLC	—		2,832		2,832
OvaXon, LLC	—		2,799		2,799
Intrexon Energy Partners, LLC	1,875		4,227		6,102
Other	2,061		7,179		9,240
Total	$	9,625	$	35,587	$	45,212

Summary of Deferred Revenue

Deferred revenue consists of the following:

	December 31,
	2016		2015
Upfront and milestone payments	$	297,867	$	181,331
Prepaid research and development services	6,015		10,938
Prepaid product and service revenues	5,554		4,759
Other	706		701
Total	$	310,142	$	197,729
Current portion of deferred revenue	$	53,364	$	35,366
Long-term portion of deferred revenue	256,778		162,363
Total	$	310,142	$	197,729

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.

	December 31,
	2016		2015
ZIOPHARM Oncology, Inc.	$	138,809	$	30,338
Oragenics, Inc.	7,766		8,813
Fibrocell Science, Inc.	19,026		21,445
Genopaver, LLC	1,977		2,250
Intrexon Energy Partners, LLC	18,125		20,625
Persea Bio, LLC	4,000		4,500
Ares Trading S.A.	47,178		53,567
Thrive Agrobiotics, Inc.	1,436		1,621
Intrexon Energy Partners II, LLC	15,833		17,833
Exotech Bio, Inc.	4,583		—
Relieve Genetics, Inc.	3,972		—
Intrexon T1D Partners, LLC	8,653		—
AD Skincare, Inc.	4,092		—
Genten Therapeutics, Inc.	4,176		—
CRS Bio, Inc.	1,949		—
Other	16,292		20,339
Total	$	297,867	$	181,331